Mylan (MYL) volatility flat into announces FDA approval of ANDAs for Glatiramer Acetate Injection

Mylan (NASDAQ: MYL) October weekly call option implied volatility is at 30, October is at 28, November is at 34; compared to its 52-week range of 23 to 51 into announcing the FDA approval of ANDAs for Glatiramer Acetate Injection.

You May Also Be Interested In

• Apple (AAPL) call put ratio 1.4 calls to 1 put
• Micron Technology (MU) call put ratio 1.1 calls to 1 put as share price up 8% into quarter results
• Intel (INTC) 20K contracts of September 60 puts trade, share price up 8.1%